Northern Trust
OBIO icon

Northern Trust’s Orchestra BioMed OBIO Stock Holding History

Northern Trust’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.48M Buy
343,640
+225,366
+191% +$922K ﹤0.01% 3301
2026
Q1 		$503K Buy
118,274
+7,375
+7% +$31.4K ﹤0.01% 3615
2025
Q4 		$460K Buy
110,899
+8,327
+8% +$33.6K ﹤0.01% 3683
2025
Q3 		$254K Buy
102,572
+2,137
+2% +$5.9K ﹤0.01% 3895
2025
Q2 		$269K Sell
100,435
-138,266
-58% -$404K ﹤0.01% 3838
2025
Q1 		$1.02M Buy
238,701
+1,940
+0.8% +$9.64K ﹤0.01% 3267
2024
Q4 		$947K Buy
236,761
+5,725
+2% +$30.8K ﹤0.01% 3420
2024
Q3 		$1.19M Buy
231,036
+87,749
+61% +$573K ﹤0.01% 3281
2024
Q2 		$1.17M Buy
143,287
+3,250
+2% +$18.8K ﹤0.01% 3173
2024
Q1 		$738K Sell
140,037
-2,842
-2% -$19.3K ﹤0.01% 3420
2023
Q4 		$1.3M Sell
142,879
-1,632
-1% -$11.1K ﹤0.01% 3214
2023
Q3 		$1.26M Buy
144,511
+88,804
+159% +$597K ﹤0.01% 3192
2023
Q2 		$390K Buy
55,707
+32,299
+138% +$490K ﹤0.01% 3604
2023
Q1 		$458K Buy
+23,408
New +$271K ﹤0.01% 3509

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Northern Trust's OBIO Position: Q2 2026 in Review

Northern Trust increased its Orchestra BioMed (OBIO) stake by 191% in Q2 2026, buying an estimated $922K and bringing the position to 343,640 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #3301.

Northern Trust first reported a position in OBIO in Q1 2023 and has held it in 14 quarters since. 77 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Northern Trust held 343,640 shares of Orchestra BioMed worth $1.48M as of Q2 2026.
  • Northern Trust bought 225,366 Orchestra BioMed shares in Q2 2026, an estimated $922K.
  • Orchestra BioMed made up ﹤0.01% of Northern Trust's portfolio in Q2 2026, its #3301 holding.
  • Northern Trust first reported a position in Orchestra BioMed in Q1 2023 and has held it in 14 quarters since.
  • 77 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Northern Trust's 13F filing for Q2 2026, filed 13 Aug 2026.